Psychotherapy, Antidepressants, and Combined Treatment for Depression: A Network Meta-analysis on Social Functioning Outcomes.

Authors

Clara Miguel, Lingyao Tong, Aran Tajika, Mathias Harrer, Nino de Ponti, Keisuke Yoshimura, Marketa Ciharova, Paul van Haaren, Claudia Buntrock, Andrea Cipriani, Georgia Salanti, Edoardo G Ostinelli, Ioana A Cristea, Pim Cuijpers, Eirini Karyotaki, Toshi A Furukawa

Published in

Psychotherapy and psychosomatics. Pages 1-20. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Social functioning is a key component of recovery in depression, yet most research on first-line treatments focuses on symptom reduction, and comparative evidence on social functioning is limited. We aimed to evaluate the comparative effects of psychotherapy, antidepressant medication, and their combination on social functioning in adults with major depression.
We conducted a systematic review and network meta-analysis of randomised controlled trials up to May 1, 2025. Eligible trials compared psychotherapy, antidepressant medication, combined treatment, and control conditions (placebo, care as usual, waitlist, or no/minimal treatment) in adults with major depression. Effects were calculated as standardised mean differences (SMD) in social functioning instruments (e.g., Sheehan Disability Scale) at post-treatment (mean 12 weeks) and follow-up (mean 32 weeks). Random-effects models were used. We assessed risk of bias and conducted sensitivity analyses. Certainty of evidence was evaluated using CINeMA.
Of 490 identified trials, 94 (19%; 23,874 participants) reported social functioning and were included. All active treatments outperformed control conditions. Effects varied substantially by control condition type, with waitlist comparisons yielding the largest estimates and comparisons against placebo or care as usual yielding more conservative effects. Combined psychotherapy and pharmacotherapy showed the largest effects versus placebo at post-treatment (SMD 0.75, 95% CI 0.57-0.94) and follow-up (1.08, 0.62-1.54). Psychotherapy and pharmacotherapy did not differ at post-treatment (SMD 0.10, 95% CI -0.05 to 0.25) or follow-up (0.27, 95% CI 0.00-0.54). Certainty of the evidence ranged from moderate to low.
First-line depression treatments support not only symptom reduction but also meaningful participation in daily life. However, only one fifth of trials assessed this outcome, highlighting the need to better integrate patient-valued outcomes into future trials.

PMID:
42340926
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.